Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway

Hepatology

Volumn 43, Issue 6, 2006, Pages 1231-1240

  Guy, Clifford S ^a   Wang, Jinguo ^a   Michalak, Tomasz I ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; COMPLEMENTARY DNA; CYTOKINE; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOASSAY; CELL CULTURE; CELL DEATH; CELL KILLING; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOODCHUCK;

ANTIGENS, CD95; APTAMERS, NUCLEOTIDE; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CELL DEATH; CELLS, CULTURED; DNA FINGERPRINTING; HEPATOCYTES; HUMANS; INTERFERON TYPE II; PROBABILITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745516867     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21201     Document Type: Article

References (49)

1. Golden-Mason L, O'Farrelly C. Having it all? Stem cells, haematopoiesis and lymphopoiesis in adult human liver. Immunol Cell Biol 2002;80:45-51.
2. Belz GT, Altman JD, Doherty PC. Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia. Proc Natl Acad Sci U S A 1998;95:13812-13817.
3. Kennedy NJ, Russell JQ, Michail N, Budd RC. Liver damage by infiltrating CD8+ T cells is Fas dependent. J Immunol 2001;167:6654-6662.
4. Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol 1999;163:3202-3210.
5. Russell JQ, Morrissette GJ, Weidner M, Vyas C, Aleman-Hoey D, Budd RC. Liver damage preferentially results from CD8(+) T cells triggered by high affinity peptide antigens. J Exp Med 1998;188:1147-1157.
6. Baumann H, Morella KK, Wong GH. TNF-alpha, IL-1 beta, and hepatocyte growth factor cooperate in stimulating specific acute phase plasma protein genes in rat hepatoma cells. J Immunol 1993;151:4248-4257.
7. Mehal WZ, Azzaroli F, Crispe IN. Antigen presentation by liver cells controls intrahepatic T cell trapping, whereas bone marrow-derived cells preferentially promote intrahepatic T cell apoptosis. J Immunol 2001;167:667-673.
8. Smedsrod B, Pertoft H, Gustafson S, Laurent TC. Scavenger functions of the liver endothelial cell. Biochem J 1990;266:313-327.
9. Diao J, Slaney DM, Michalak TI. Modulation of the outcome and severity of hepadnaviral hepatitis in woodchucks by antibodies to hepatic asialoglycoprotein receptor. HEPATOLOGY 2003;38:629-638.
10. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995;75:591-609.
11. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
12. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
13. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-37.
14. Roth E, Pircher H. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. J Immunol 2004;172:1588-1594.
15. Kishimoto H, Surh CD, Sprent J. A role for Fas in negative selection of thymocytes in vivo. J Exp Med 1998;187:1427-1438.
16. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-444.
17. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073-1083.
18. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 1996;157:2909-2915.
19. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-370.
20. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
21. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med 1999;189:441-446.
22. Roskams T, Libbrecht L, Van Damme B, Desmet V. Fas and Fas ligand: strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoural cells? J Pathol 2000;191:150-153.
23. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230.
24. Strand S, Hofmann WJ, Grambihler A, Hug H, Volkmann M, Otto G, et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 1998;4:588-593.
25. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
26. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997;158:5692-5697.
27. Michalak TI. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 2000;174:98-111.
28. Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 2004;127:S283-S293.
29. Hodgson PD, Michalak TI. Augmented hepatic interferon gamma expression and T-cell influx characterize acute hepatitis progressing to recovery and residual lifelong virus persistence in experimental adult woodchuck hepatitis virus infection. HEPATOLOGY 2001;34:1049-1059.
30. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004;101:6669-6674.
31. Diao J, Churchill ND, Michalak TI. Complement-mediated cytotoxicity and inhibition of ligand binding to hepatocytes by woodchuck hepatitis virus-induced autoantibodies to asialoglycoprotein receptor. HEPATOLOGY 1998;27:1623-1631.
32. Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J Virol 2001;75:1770-1782.
33. Ebata T, Mogi S, Hata Y, Fujimoto JI, Yagita H, Okumura K, et al. Rapid induction of CD95 ligand and CD4+ T cell-mediated apoptosis by CD137 (4-1BB) costimulation. Eur J Immunol 2001;31:1410-1416.
34. Hodgson PD, Grant MD, Michalak TI. Perform and Fas/Fas ligand-mediated cytotoxicity in acute and chronic woodchuck viral hepatitis. Clin Exp Immunol 1999;118:63-70.
35. Churchill ND, Michalak TI. Woodchuck hepatitis virus hepatocyte culture models. Methods Mol Med 2004;96:175-187.
36. Wang J, Michalak TI. Comparison of biological activity of recombinant woodchuck interferon gamma and tumor necrosis factor alpha produced in baculovirus and Escherichia coli expression systems. Cytokine 2005;30:22-34.
37. Michalak TI, Hodgson PD, Churchill ND. Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection. J Virol 2000;74:4483-4494.
38. Coffin CS, Michalak TI. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J Clin Invest 1999;104:203-212.
39. Michalak TI, Pardoe IU, Coffin CS, Churchill ND, Freake DS, Smith P, et al. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. HEPATOLOGY 1999;29:928-938.
40. 51Cr-release assay to assess the cytotoxicity of dendritic cells on hematopoietic tumor cells. Immunol Invest 2003;32:219-227.
41. Matzinger P. The JAM test: a simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-192.
42. Kuwano K, Arai S. Involvement of two distinct killing mechanisms in bystander target cell lysis induced by a cytotoxic T lymphocyte clone. Cell Immunol 1996;169:288-293.
43. Sarin A, Haddad EK, Henkart PA. Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J Immunol 1998;161:2810-2816.
44. Suzuki I, Fink PJ. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc Natl Acad Sci U S A 2000;97:1707-1712.
45. Kojima Y, Kawasaki-Koyanagi A, Sueyoshi N, Kanai A, Yagita H, Okumura K. Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity. Biochem Biophys Res Commun 2002;296:328-336.
46. Moers C, Warskulat U, Muschen M, Even J, Niederacher D, Josien R, et al. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer 1999;80:564-572.
47. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66:1403-1408.
48. Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Ju ST. Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J Immunol 1998;161:3469-3473.
49. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000;6:920-923.